June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Treat and Extend versus Relaxed Pro Re Nata Regimens of Ranibizumab in Diabetic Macular Edema: a two-year real-world matched comparison study
Author Affiliations & Notes
  • Yi-Ting Hsieh
    National Taiwan University Hospital, Taipei, Taiwan
  • Tso-Ting Lai
    National Taiwan University Hospital, Taipei, Taiwan
  • Chung-May Yang
    National Taiwan University Hospital, Taipei, Taiwan
  • Chang-Hao Yang
    National Taiwan University Hospital, Taipei, Taiwan
  • Tzyy-Chang Ho
    National Taiwan University Hospital, Taipei, Taiwan
  • Footnotes
    Commercial Relationships   Yi-Ting Hsieh, Novartis Taiwan (F), Novartis Taiwan (C), Novartis Taiwan (R); Tso-Ting Lai, Novartis Taiwan (C), Novartis Taiwan (R); Chung-May Yang, Novartis Taiwan (C); Chang-Hao Yang, Novartis Taiwan (C); Tzyy-Chang Ho, Novartis Taiwan (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3303. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yi-Ting Hsieh, Tso-Ting Lai, Chung-May Yang, Chang-Hao Yang, Tzyy-Chang Ho; Treat and Extend versus Relaxed Pro Re Nata Regimens of Ranibizumab in Diabetic Macular Edema: a two-year real-world matched comparison study. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3303.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the treatment outcomes of treat and extend (T&E) versus relaxed pro re nata (PRN) regimens of ranibizumab in treating diabetic macular edema (DME).

Methods : Patients who received a T&E regimen of ranibizumab with 3 loading doses for the treatment of DME were retrospective recruited as the study group. Those who received a relaxed PRN regimen with follow-up intervals of 2 to 3 months after the 3 loading doses and were matched to the cases in the study group by baseline best-corrected visual acuity (BCVA) and central subfield thickness (CST) were enrolled as the control group. The change in BCVA and CST at Month 24, standard deviation of BCVA and CST between Month3 and Month 24, and injection numbers were compared between two groups.

Results : There were 34 eyes from 34 patients in each group. The mean logMAR of BCVA improved from 0.72 ± 0.33 at baseline to 0.40 ± 0.29 at Month 24 in the T&E group, and improved from 0.71 ± 0.31 at baseline to 0.54 ± 0.41 at Month 24 in the relaxed PRN group. The visual improvement in the T&E group was better than that in the relaxed PRN group through Month 6 to Month 24 (P < 0.05 for all). The mean injection numbers during the first year and during the second year were 7.6 ± 1.8 and 3.6 ± 1.9, respectively in the T&E group, and were 4.9 ± 1.5 and 1.3 ± 1.2, respectively, in the relaxed PRN group (P < 0.05 for both). The standard deviation of CRT in the T&E group (39.7 ± 38.0 μm) was less than that in the relaxed PRN group (67.0 ± 74.9 μm) (P = 0.027).

Conclusions : The T&E regimen of ranibizumab resulted in better visual improvement and less fluctuation of CRT than the relaxed PRN regimen in treating DME.

This is a 2020 ARVO Annual Meeting abstract.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×